Abstract is: William Douglas Figg Sr. (born August 22, 1963 in Owensboro, Kentucky) is an American scientist (pharmacologist) at the National Institutes of Health, Bethesda, Maryland.
| human | Q5 |
| P2381 | Academic Tree ID | 596506 |
| P268 | Bibliothèque nationale de France ID | 14565143k |
| P8179 | Canadiana Name Authority ID | ncf11362958 |
| P11496 | CiNii Research ID | 1140282266630584960 |
| P1280 | CONOR.SI ID | 295097443 |
| P6178 | Dimensions author ID | 015133432202.50 |
| 016550720157.32 | ||
| P646 | Freebase ID | /m/0j3fw5f |
| P1960 | Google Scholar author ID | hsCRZ3QAAAAJ |
| P269 | IdRef ID | 078841828 |
| P213 | ISNI | 0000000041350921 |
| P244 | Library of Congress authority ID | n2004008731 |
| P2798 | Loop ID | 25699 |
| P271 | NACSIS-CAT author ID | DA16420967 |
| P8189 | National Library of Israel J9U ID | 987007369327305171 |
| P950 | National Library of Spain ID | XX1729957 |
| P1015 | NORAF ID | 4057254 |
| P496 | ORCID iD | 0000-0003-2428-5613 |
| P3368 | Prabook ID | 442295 |
| P2038 | ResearchGate profile ID | William-Figg-2 |
| P1153 | Scopus author ID | 35377337900 |
| P214 | VIAF ID | 49466340 |
| P10832 | WorldCat Entities ID | E39PCjM4TYhWCMTwvGDMf886Kd |
| P2002 | X username | williamfigg1 |
| P27 | country of citizenship | United States of America | Q30 |
| P108 | employer | National Cancer Institute | Q664846 |
| P734 | family name | Figg | Q37503606 |
| Figg | Q37503606 | ||
| Figg | Q37503606 | ||
| P8017 | generational suffix | L252248-F2 | |
| P735 | given name | Douglas | Q463035 |
| Douglas | Q463035 | ||
| William | Q12344159 | ||
| William | Q12344159 | ||
| P106 | occupation | pharmacologist | Q2114605 |
| P21 | sex or gender | male | Q6581097 |
| Q28611188 | 2-Methoxyestradiol, a promising anticancer agent |
| Q114027420 | A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities |
| Q112280630 | A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma |
| Q33440392 | A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. |
| Q64111238 | A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma |
| Q34392792 | A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer |
| Q33725993 | A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. |
| Q30847916 | A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma |
| Q33397124 | A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas |
| Q33345375 | A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. |
| Q33417499 | A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. |
| Q36953368 | A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. |
| Q33213907 | A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy |
| Q104479080 | A very long-acting Poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models |
| Q37297173 | ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel |
| Q112639649 | Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics |
| Q92462025 | Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime? |
| Q33611121 | Angiogenesis inhibitors in the treatment of prostate cancer |
| Q104071294 | Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs |
| Q36545959 | Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? |
| Q35148088 | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia |
| Q36015058 | Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer |
| Q37020542 | Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. |
| Q35669792 | CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv |
| Q34929404 | CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents |
| Q97548981 | COVID-19 Clinical Diagnostics and Testing Technology |
| Q28303421 | CYP2D6 polymorphisms and the impact on tamoxifen therapy |
| Q38795045 | Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. |
| Q104284502 | Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD |
| Q33313083 | Clinical and molecular responses in lung cancer patients receiving Romidepsin |
| Q37657540 | Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. |
| Q30432069 | Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis |
| Q33380559 | Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity |
| Q90910007 | Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy |
| Q37589638 | Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. |
| Q33704464 | Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. |
| Q28551021 | Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease |
| Q33433160 | Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry |
| Q33431691 | Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection |
| Q112701466 | Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors |
| Q35600382 | Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells |
| Q24658301 | Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer |
| Q33425469 | Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. |
| Q99564651 | Efficacy, tolerability and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma |
| Q54945631 | Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy. |
| Q34622545 | Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy |
| Q36607842 | Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 |
| Q92104678 | Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models |
| Q21091035 | Expression of OATP family members in hormone-related cancers: potential markers of progression |
| Q33638830 | Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. |
| Q28547130 | Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial |
| Q34581740 | Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer |
| Q34663656 | Genetic variation: effect on prostate cancer. |
| Q34036032 | Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib |
| Q92380295 | IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion |
| Q34781769 | Impact of ABCB1 allelic variants on QTc interval prolongation |
| Q28538733 | Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance |
| Q35001199 | Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2 |
| Q34722263 | Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer |
| Q37715400 | Integrating pharmacogenetic information and clinical decision support into the electronic health record |
| Q33726989 | Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma |
| Q36524183 | Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer |
| Q96230172 | Metastasis-specific gene expression in autochthonous and allograft mouse mammary tumor models: stratification and identification of targetable signatures |
| Q28388640 | Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells |
| Q33224548 | Molecular alterations in primary prostate cancer after androgen ablation therapy |
| Q37672642 | More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer |
| Q37721951 | Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. |
| Q88633019 | Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors |
| Q98457944 | PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA |
| Q36425250 | Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention |
| Q37120546 | Pharmacogenetics of membrane transporters: a review of current approaches |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q35118358 | Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors |
| Q33394324 | Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma |
| Q33259359 | Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura |
| Q24644011 | Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies |
| Q33600521 | Phase I study of oral lenalidomide in patients with refractory metastatic cancer |
| Q28266067 | Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies |
| Q33417803 | Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms |
| Q33394689 | Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. |
| Q33341474 | Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms |
| Q33415400 | Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses |
| Q33440778 | Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. |
| Q33386623 | Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma |
| Q37136248 | Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity |
| Q33406047 | Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer |
| Q33813626 | Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer |
| Q33429309 | Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. |
| Q33364957 | Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer |
| Q33343536 | Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation |
| Q90347931 | Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization |
| Q99210576 | Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors |
| Q35183640 | Population pharmacokinetic analysis of sorafenib in patients with solid tumours. |
| Q37253554 | Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma |
| Q90369452 | Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models |
| Q35863853 | Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis |
| Q61136651 | Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases |
| Q33418729 | Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer |
| Q33390876 | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. |
| Q28743602 | Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers |
| Q24609511 | Sarcosine as a potential prostate cancer biomarker and therapeutic target |
| Q30479632 | Selective leukemic-cell killing by a novel functional class of thalidomide analogs |
| Q90429155 | Selumetinib in Children with Inoperable Plexiform Neurofibromas |
| Q33435557 | Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. |
| Q96589382 | Slow tight binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen |
| Q33360075 | Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed? |
| Q34722277 | Suramin's development: what did we learn? |
| Q89907295 | Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro |
| Q121034172 | Targeting the metastatic niche: Single-cell lineage tracing in prime time |
| Q24670383 | Thalidomide analogues as anticancer drugs |
| Q24653215 | Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation |
| Q34676948 | The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity |
| Q31057714 | The canSAR data hub for drug discovery. |
| Q35709974 | The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer |
| Q37362585 | The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors |
| Q37735146 | Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy |
| Q34151732 | Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy |
| Q33429235 | UGT genotyping in belinostat dosing |
| William Douglas Figg Sr. | wikipedia |
Search more.